Formulary
Delamanid: Indications, Dosing, Side Effects and Interactions
Delamanid clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Delamanid: Indications, Dosing, Side Effects and Interactions
Delamanid clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Multiple-drug resistant pulmonary tuberculosis, in combination with other drugs**
- **Adult** (By Mouth): 100 mg twice daily for 24 weeks, continue appropriate combination therapy after delamanid.
Cautions
Risk factors for QT interval prolongation (e.g. electrolyte disturbances, acute myocardial infarction, heart failure with reduced left ventricular ejection fraction, severe hypertension, left ventricular hypertrophy, bradycardia, congenital long QT syndrome, history of symptomatic arrhythmias)
Contraindications
QTc interval more than 500 milliseconds (derived using Fridericia's formula); serum albumin less than 28 g/litre
Side effects
Common or very common Anxiety; appetite decreased; asthenia; chest pain; cough; depression; dyslipidaemia; dyspnoea; ear pain; electrolyte imbalance; gastrointestinal discomfort; haemoptysis; headache; hyperhidrosis; hypertension; hypotension; malaise; muscle weakness; nausea; oropharyngeal pain; osteochondrosis; pain; palpitations; peripheral neuropathy; photophobia; psychotic disorder; QT interval prolongation; reticulocytosis; sensation abnormal; skin reactions; sleep disorders; throat irritation; tinnitus; tremor; vomiting Uncommon Aggression; atrioventricular block; balance impaired; dehydration; delusional disorder, persecutory type; dysphagia; extrasystole; hepatic function abnormal; increased risk of infection; lethargy; leucopenia; oral paraesthesia; psychiatric disorders; thrombocytopenia; urinary disorders
Interactions
**Other interactions (2):**
- Delamanid (100 mg BID) (Lopinavir/ritonavir 400/100 mg BID) Delamanid: AUC: 22% DM-6705 (delamanid active metabolite): AUC: 30% A more pronounced effect on DM-6705 exposure may be observed...
- Due to the risk of QTc prolongation associated with DM-6705, if co-administration of delamanid with Kaletra is considered necessary, very frequent ECG monitoring throughout the full delamanid...
Pregnancy
Manufacturer advises avoid-toxicity in animal studies.
Breast feeding
Manufacturer advises avoid-present in milk in animal studies.
Hepatic impairment
Manufacturer advises avoid in moderate to severe impairment.
Renal impairment
Manufacturer advises avoid in severe impairment-no information available.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Delamanid in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

